There is a new twist in the long-running dispute over who owns patent rights to the Nobel prize-winning Crispr–Cas9 gene editing technology.
A team including Nobel laureates Jennifer Doudna and Emmanuelle Charpentier lost its claim to key
There is a new twist in the long-running dispute over who owns patent rights to the Nobel prize-winning Crispr–Cas9 gene editing technology.
A team including Nobel laureates Jennifer Doudna and Emmanuelle Charpentier lost its claim to key